Search

everythinglearnresearchcommunity

for

Search:↓

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Erlotinib can cause nonscarring hair loss and itchy skin.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

A man developed skin issues from cancer medication, which improved with specific treatments.

Tofacitinib may effectively treat folliculitis decalvans.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

A woman's hair turned white after taking a cancer drug called dasatinib.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Tideglusib helps heal wounds in older skin.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Certain cancer drugs can cause skin issues like rashes and itching.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.